Search results

• Leveraging Group-wide capabilities to accelerate the development of natural active ingredients

  The move in cosmetics towards replacing synthetic ingredients with sustainable alternatives is increasing demand for naturally sourced actives.

• Bio based Industry Story of the Year Winner

  Croda have been awarded the 2019 Bio-Based World News Innovation Award for “Bio-based Industry Story of the Year”

• Transition to bio-based MPG

  Transitioning our raw materials to bio-based sources will enable us to make a significant positive impact.

• Commitment to Science Based Targets

  We are proud to be one of around 600 companies taking science-based climate action, by committing to Science Based Targets

• 1.5°C science-based target validation

  In July 2021 we became only the third major chemical company globally to have a 1.5ºC science-based target validated.

• Acquisition of global vaccine adjuvant specialist

  Vaccine adjuvants are a natural extension to Croda’s market leading, high-purity excipient delivery systems in its Health Care business., these adjuvants represent a niche, high-growth market.

• Croda acquires research enterprise Enza Biotech

  Developing the next generation of renewable surfactants using carbohydrate-based chemistry.

• Acquisition of global vaccine adjuvant specialist

  Vaccine adjuvants are a natural extension to Croda’s market leading, high-purity excipient delivery systems in its Health Care business., these adjuvants represent a niche, high-growth market.

• Investing in mRNA and gene therapy

  As the core of our lipid systems capability within the Health Care business, Avanti is primarily focused on developing innovative lipid-based products of unparalleled purity to address specific medical challenges that are not resolved by current technology.

• Meet the expert: Dhanila Varkey, Applications Team Lead

  Discover how Croda’s applications expert Dhanila Varkey is using nanotechnology to improve targeting, absorption and effectiveness in topical and transdermal drug delivery.

• Supplying delivery systems to help prevent cardiovascular disease

  Nucleic acid-based therapies are the next big blockbuster drug class opening up exciting applications such as gene editing, where a patient’s genetic material can be modified to correct a disorder.

• Croda acquires marine biotechnology specialists Nautilus

  World class scientists, focusing on using marine microbial biodiversity to discover novel actives and materials for applications across all Croda market sectors.

• Croda expands Iberchems fragrances offering with the acquisition of Parfex

  Croda has acquired a controlling majority 95.6% of Parfex’s outstanding shares, comprising the founding shareholders and certain minority investors.

• Acquisition of Alban Muller

  The acquisition expands Croda’s portfolio of sustainable active ingredients for customers in personal care markets.

• Validation of our 1.5°C Science Based Targets

  We have become one of only three major chemical companies in the world to have our 1.5°C Science Based Targets validated.

• Croda and Anome Collaboration Promises a Positive Difference in Beauty Effects

  We are very proud to announce a new collaborative partnership with Anomera, an award-winning innovator in green chemistry, materials science and sustainable manufacturing.

• Construction underway on our new North American Headquarters and innovation centre

  The sustainable facility will bring together commercial and technical teams from across our business areas

• Celebrating our innovative ingredients: Zenakine™ - redefining neurocosmetic skincare possibilities

  8 September 2025: Croda International Plc (“Croda”), the company that uses smart science to create high-performance ingredients and solutions that improve lives, has recently launched Zenakine™, a biotech-based neuroactive ingredient designed to counteract the effects of stress on the skin.

• Life Sciences

  We provide high-quality healthcare solutions, protect crops, and enhance seeds, supporting global health and crop sustainability. Our growing range of technologies ensures we deliver high value to customers worldwide.

• Our timeline

  View our timeline to discover how we became the global leader in naturally resourced, speciality chemicals.

• Launch of Croda Pharma

  23 May 2022: Our Health Care division becomes Croda Pharma

• Croda joins KTN SME accelerator programme

  Supporting UK-based SMEs and start-ups to bring their technology closer to market through the KTN accelerator programme

• Transition to a dedicated Consumer Care and Life Sciences company

  Croda enters agreement to sell majority of Performance Technologies and Industrial Chemicals businesses; completing its transition into a dedicated Consumer Care and Life Sciences company

• Record financial performance strategy executed with agility

  1 March 2022: Results for the year ended 31 December 2021.

• Reinventing Surfactants for Sustainability

  Our 100 percent bio-based, 100 percent renewable, ECO range of surfactants are now available

• Oil and Gas Portfolio Strengthened by Acquisition

  Global speciality chemical manufacturer Croda, announces the acquisition of JD Horizons Limited, a UK based business specialising in ‘Solutions for Flow Assurance’ technology.

• Centre of Innovation for Marine Biotechnology

  Nautilus Biosciences officially opens its expanded UPEI-based facility as a Centre of Innovation for Marine Biotechnology

• Croda Brings Another First to USA

  Starting production to make a 100 percent bio-based ECO range of surfactants

• Sustainability success with EcoVadis rating

  24 May 2022: Sustainability success after retaining its position within the top 1% of companies assessed by EcoVadis

• 2025 Full Year Results

  Encouraging early progress delivering on our plan to grow earnings and improve returns.

• USA

  Croda Inc is the North American headquarters for Croda, with over 800 employees, working in a variety of roles in manufacturing, sales, marketing and research and development.

• Analyst consensus

  Consensus collated from estimates submitted by side-sell analysts on Croda International Plc.

• EMEA

  Our global headquarters are based in Yorkshire in the UK. We also have a number of offices and manufacturing sites spread across the region.

• Launching futures

  Embarking on excellence with our transformative graduate scheme

• Biotechnology at Croda

  Our innovation is focused on sustainability and, in particular, biotechnology, enhancing the sustainability of our processes and products.

• Smart science

  Innovation drives us to achieve our Purpose, from the ingredients we create and how we operate, to the natural, renewable raw materials that we use.

• Behind the Science

  Discover how Croda’s high-quality ingredients, scientific expertise and sustainable innovation deliver end-to-end solutions that power growth across Consumer Care and Life Sciences.

• Canada

  Croda Canada was established in 1968 with its office based in Vaughan, Ontario.

• New white paper from Croda Agriculture highlights science-led innovation in regenerative agriculture

  27 October 2025: Croda International Plc  releases a new white paper that provides a comprehensive, evidence-based exploration of regenerative agriculture and the innovations helping to transform the agricultural sector.

• Spain

  Croda Iberica is based in Barcelona and was set up in 1998.

• Abiotic stress mitigation in onions

  Changing climates mean higher temperatures, periods of drought and higher salinity are becoming an increasing problem for farmers.

• Careers

  Here at Croda, our people and operations are what make us who we are, we have people across the world, operating in 37 different countries.

• Net zero roadmap for UK manufacturing site

  We became one of the first UK manufacturing sites to develop a 2050 net zero roadmap as part of the UK Government’s Department for Business, Energy and Industrial Strategy ‘Industry of the Future’ programme.

• Leveraging expertise in UV filters for Asian markets

  There are over three million cases of skin cancer globally each year, responsible for tens of thousands of deaths. Our range of sunscreens meets a clear need and is an important pillar of our sustainability Commitment to be People Positive by 2030.

• Collaboration to deliver new vaccine adjuvants

  In 2021 we established a strategic collaboration with the Danish government’s life science research institute, Statens Serum Institute (SSI).

• Waste management

  Iberchem, our global fragrance and flavours business based in Spain, has championed waste management best practices through robust policies and employee education programmes.

• Supporting the next generation of therapeutic vaccines

  Vaccine adjuvants are used to enhance immune response to an antigen, improving the overall efficacy of the vaccine and increasing protection against the target disease.

• Sustainability-linked revolving credit facility

  In 2019, we became one of the UK’s first large public companies to include a sustainability metric in a revolving credit facility (RCF), with targets in the seven-year agreement aligned with our 2030 Commitment to become Climate Positive.

• Collaboration to develop alternative vaccine adjuvants

  In 2021 we established a strategic collaboration with the Danish Government’s life science research institute, Statens Serum Institute (SSI).

• Sustainability without compromise ChromaPur

  Small, manufactured plastic particles, known as microbeads, are used in a wide range of cosmetic and personal care products, with research suggesting that 87% of products from the ten best-selling cosmetics brands contain these microplastics.